Cambridge University highlights data for alemtuzumab in MS

Thursday 23 October 2008

The University of Cambridge is highlighting the results of a Phase 2 study of the monoclonal antibody alemtuzumab which, it says, shows the drug has promise for treating people with multiple sclerosis.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom